[Study of the biochemical and radiochemical effects of the agent MTDQ (author's transl].
The antioxidant MTDQ exhibits a radiosensitizing effect and was used in pretreatment of radiation-resistant human tumors, e.g. synoviomas, sarcomas, von Recklinghausen disease. After this premedication and fractionated radiation therapy of different kinds a permanent regression of the tumors was observed. The radiosensitizing compound is non-toxic and selectively accumulates in tumorous tissues. The chemical structure (three functional groups) and in vitro tests make probable that the main factors in the mechanism of action are peroxide decomposition, hydrol formation, polymerization and, in the course of those reactions, the in situ release of oxygen.
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D006801:Humans; D051379:Mice; D009456:Neurofibromatosis 1 / Q000532:radiotherapy; D011804:Quinolines / Q000494:pharmacology*; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*; D051381:Rats; D012509:Sarcoma / Q000532:radiotherapy; D013584:Sarcoma, Synovial / Q000532:radiotherapy
D000975:Antioxidants; D011804:Quinolines; D011838:Radiation-Sensitizing Agents
Beitrag zu den bio- und radiochemischen Wirkungen der Verbindung MTDQ.